| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Hyperfine, Inc.$1.09
-0.01 (-1.32%)
F 5Pipeline Score MedTech · Commercial
Market Cap
147.91 M
EPS
-0.41
P/E Ratio
-
Value Trade
707.87 K
SEC Financials
Q1 2026Dilution Risk
40%Revenue
3.90 M
R&D Expenses
3.85 M
Operating CF
-9.01 M
Total Assets
60.34 M
Total Liabilities
25.98 M
Equity
34.36 M
D/E Ratio
12,345
-6.88 %
Week
14.62 %
1 Month
31.85 %
3 Month
46.08 %
6 Month
-84.65 %
5 Year
-85.67 %
All Time
Cash Data
Cash Position
40.78 M
Monthly Burn
3.00 M
Runway
11.9 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
943.17 K
52 Week Range
0.54 - 2.22
% held by Insiders
21.26 %
% held by Institutions
11.42 %
Enterprise Value
120.00 M
Total Shares
83.42 M
Short %
4.84 %
Float Shares
69.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hyperfine, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Drug Pipeline Intelligence
F5
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 5%
Micro Cap (rank 866 of 911)
Percentile RankHyperfine, Inc. has significant pipeline risk (5/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Swoop® system | stroke detection | — | 2026-01-27 | 95 patients, dramatic improvements in diagnostic performance | Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection Capabilities Read More | |
Swoop® system | stroke detection | — | 2026-01-27 | 95 patients, dramatic improvements in diagnostic performance | Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection Capabilities Read More | |
Swoop® system | stroke detection | — | 2026-01-27 | 95 patients, dramatic improvements in diagnostic performance | Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection Capabilities Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HYPR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HYPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HYPRHyperfine Announces European Launch of Next-Generation Swoop® System
Hyperfine has announced the European launch of its next-generation Swoop® system. This development is aimed at enhancing medical imaging capabilities. Further details about the technology and its applications were not provided in the announcement.
Read more →HYPR▼ -6.9%on this news
Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care
Hyperfine has established a Global Neurosurgery Advisory Council aimed at promoting the use of portable MRI technology in neurosurgical care. This initiative is expected to enhance patient outcomes by providing more accessible imaging solutions. The council will consist of experts dedicated to advancing the integration of portable MRI in clinical practice.
Read more →HYPR▲ +15.1%on this newsshared move
Hyperfine Swoop® System Scan Volume in the United States Hits Record Milestones Across Multiple Sites of Care
Hyperfine's Swoop® System has reportedly achieved record scan volumes across various care sites in the United States. However, the article provides minimal details regarding these milestones, leaving questions about the significance of the achievements. The lack of specific data may affect the perceived impact of this news.
Read more →HYPRHyperfine, Inc. Reports First Quarter 2026 Financial Results
Hyperfine, Inc. has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance during this period. However, specific details regarding revenue, expenses, or future projections were not included in the text provided.
Read more →HYPRHyperfine, Inc. to Participate in Upcoming 2026 Jefferies Global Healthcare Conference
Hyperfine, Inc. is set to participate in the 2026 Jefferies Global Healthcare Conference. The event will provide a platform for the company to showcase its innovations and engage with industry stakeholders. Details about the specific topics to be discussed or presented at the conference have not been disclosed.
Read more →HYPRHyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Hyperfine, Inc. reported strong financial results for the fourth quarter and full year 2025, with revenues up 128% in Q4 compared to the previous year. The company launched a second-generation Swoop scanner and received FDA clearance for advanced AI software, enhancing brain MRI capabilities. Despite these positive developments, Hyperfine experienced a net loss of $5.91 million in Q4 2025, indicating ongoing financial challenges. Looking forward, management projects significant revenue growth for 2026, supported by new product offerings and international market expansion.
Read more →HYPR▲ +10.1%on this news
Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System’s Enhanced Stroke Detection Capabilities
Hyperfine, Inc. announced significant findings from a multi-center study evaluating the Swoop® system's stroke detection capabilities. The research demonstrated improved sensitivity and specificity in identifying ischemic lesions using advanced DWI sequences. This advancement supports the integration of portable MRI systems in emergency departments, potentially enhancing patient care and timely evaluations.
Read more →HYPRHyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics
Hyperfine, Inc. announced positive results from the NEURO PMR study, showcasing the Swoop® portable MRI system's high diagnostic value and superior patient experience in neurology clinics. The study demonstrated a 92% concordance with standard MRI and a significant preference among patients for the portable system. The Swoop® system's ease of use and operational efficiency could revolutionize imaging in outpatient settings.
Read more →HYPRHyperfine Announces Enrollment of First Patient in Study to Expand Intended Use of the Swoop® System with Contrast Agents
Hyperfine, Inc. has announced the enrollment of the first patient in its Contrast PMR study, aimed at evaluating the use of contrast agents with its Swoop® portable MRI system. This study seeks to assess the visualization of brain lesions and could support a future FDA submission to expand the system's intended use. The study will involve approximately 70 patients across multiple sites in the U.S.
Read more →HYPRHyperfine Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results Hyperfine Delivers Quarterly Record Revenue of Approximately $5.3 Million in Q4 2025, Representing Transformative Growth of 54%
Hyperfine, Inc. reported preliminary unaudited financial results for the fourth quarter and full year of 2025. The company achieved a record revenue of approximately $5.3 million in Q4 2025, reflecting a significant growth of 54% compared to the previous quarter. CEO Maria Sainz highlighted success in multiple business verticals, including hospital placements and international markets. A complete financial outlook is expected in their upcoming Q4 earnings call in March 2026.
Read more →HYPRHyperfine Announces Regulatory Approval of the Swoop® System in India
Hyperfine, Inc. has received regulatory approval for its Swoop® portable MRI system from India's CDSCO. This approval allows for commercialization throughout India, addressing the country's significant unmet need for accessible brain imaging. The partnership with Radiosurgery Global will facilitate the distribution of this innovative technology, enhancing healthcare delivery in diverse settings.
Read more →HYPRHyperfine, Inc. Reports Third Quarter 2025 Financial Results
Hyperfine, Inc. reported its financial results for Q3 2025, indicating a revenue increase of 27% to $3.4 million. The company successfully commercialized its next generation Swoop system and Optive AI software, and has placed systems across various U.S. healthcare settings. Despite these advancements, Hyperfine experienced a net loss of $11 million, and raised $20.1 million to bolster its financial position for further growth. The company provided Q4 2025 revenue guidance of $5 to $6 million, indicating anticipated sequential and year-over-year increases.
Read more →HYPR▼ -35.5%on this news
Hyperfine Announces Pricing of $17.5 Million Public Offering GUILFORD, CT.
Hyperfine, Inc. has announced the pricing of its underwritten public offering, selling 14 million shares of Class A common stock at $1.25 each, aiming to raise approximately $17.5 million. The offering is expected to close on or about October 17, 2025, pending customary closing conditions. Proceeds will be allocated to working capital and general corporate purposes, enhancing their research, manufacturing, and commercial capabilities. Lake Street Capital Markets, LLC is the sole book-runner for the offering.
Read more →HYPR▲ +7.3%on this news· ran to -37% by day 3shared move
Hyperfine Reports Preliminary, Unaudited Results for Third Quarter 2025, Signaling Strong Business Momentum Following the Launch of the Next Generation Swoop System Guilford, CONN.
Hyperfine, Inc. reported preliminary, unaudited financial results for Q3 2025, highlighting strong demand for its next-generation Swoop portable MRI system and Optive AI software. CEO Maria Sainz noted notable market excitement and consistent revenue growth as the company underwent several successful hospital deal closures. The results are anticipated to strengthen the company's position moving into the latter half of the year. However, the financial data remains subject to further audit and adjustments.
Read more →HYPR▲ +14.2%on this news
Hyperfine, Inc. Reports Second Quarter 2025 Financial Results
Hyperfine, Inc. reported its second quarter 2025 financial results, highlighting significant milestones including FDA clearances for its new software and the next generation Swoop system. The company completed a pilot program in neurology and expressed optimism for growth in the latter half of 2025. CEO Maria Sainz emphasized strong financial performance and disciplined spending.
Read more →HYPRHyperfine, Inc. Reports First Quarter 2025 Financial Results
Hyperfine, Inc. announced its first quarter 2025 financial results, reporting revenues of $2.1 million, down from $3.3 million in the same period last year. Despite longer sales cycles in the hospital sector, the company is optimistic about its expansion into neurology offices and upcoming FDA clearances that may enhance its product offering. Management forecasts a potential revenue growth of 10% to 20% for the full year 2025, while also addressing a reduced cash burn.
Read more →HYPR▲ +39.3%on this news
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
Hyperfine, Inc. (Nasdaq: HYPR) reported its financial results for Q4 and the full year 2024, revealing a 17% year-over-year revenue increase. The fourth quarter saw revenues of $2.32 million, a slight decline from the same period in 2023. The company also announced plans to launch two AI-powered software products in 2025, which are expected to enhance imaging capabilities. However, it incurred a net loss of $40.72 million for the full year, despite raising $6 million to extend its operational runway.
Read more →HYPR▼ -32.9%on this news
AI-Powered, Portable Brain MRI The Swoop Portable MR Imaging system is driving the future of brain health. Corporate Investor Deck Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PR
Hyperfine, Inc. is advancing its Swoop Portable MRI system, which is designed to provide diagnostic-quality brain imaging with broad FDA clearance. The company emphasizes significant market potential, projecting a growing addressable market in the U.S. for its innovative imaging technology. However, Hyperfine also cautions investors about uncertainties that could affect future performance and the acceptance of their products in the healthcare sector. The company's recent milestones and software innovations highlight its commitment to improving imaging technology.
Read more →HYPR▼ -32.9%on this news
Hyperfine Announces $6.0 Million Registered Direct Offering GUILFORD, CT.
Hyperfine, Inc. has announced a definitive agreement for a registered direct offering, aiming to sell 4,511,278 shares of Class A common stock at a price of $1.33 per share, yielding approximately $6.0 million in gross proceeds. The offering is set to close on February 12, 2025, subject to customary conditions. The company plans to utilize the proceeds for working capital, including manufacturing and R&D activities. This move is expected to bolster Hyperfine's ongoing efforts in developing its innovative Swoop brain imaging system.
Read more →HYPRHyperfine, Inc. Reports Third Quarter 2024 Financial Results
Hyperfine, Inc. reported its third quarter 2024 financial results, highlighting a revenue increase of 56% to a record $3.64 million. The company saw improvements in gross margin, reaching 52%, coupled with successful technology advancements, including the rollout of AI-powered brain imaging software. Despite the positive growth indicators, it recorded a net loss of $10.33 million while projecting a cash burn of $37 to $40 million for the year. Management expressed confidence in future growth prospects as they pursue expansion strategies.
Read more →HYPRHyperfine, Inc. Reports Record Quarterly Revenue and Raises FY 2024 Revenue Guidance ─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin ─ Raises FY 2024 Revenue Guidance to $13-16M
Hyperfine, Inc. announced a record quarterly revenue of $3.63 million for Q2 2024 and has raised its FY 2024 revenue guidance to a range of $13-16 million. The company also reported a net loss of $10.16 million, although this is an improvement compared to the previous year. Notable achievements include FDA clearance for its 9th generation AI-powered brain imaging software and progress in clinical studies related to Alzheimer's care. Hyperfine continues to expand its market presence with new distributors in key regions.
Read more →HYPRHyperfine, Inc. Reports First Quarter 2024 Financial Results
Hyperfine, Inc. has reported promising financial results for the first quarter of 2024, showing a 25% increase in revenue compared to the previous year. Significant milestones include the launch of their 8th generation AI-powered software and the commencement of enrollment in key clinical studies. Despite these achievements, the company recorded a net loss of $9.85 million and anticipates a substantial cash burn for the year. Management maintains a positive outlook, forecasting annual revenues between $12 million and $15 million.
Read more →HYPRHyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Hyperfine, Inc. reported its fourth quarter and full year 2023 financial results, showcasing a significant revenue increase of 62% year-over-year. The company emphasized strong growth in critical care and pediatrics markets, alongside new programs targeting Alzheimer's disease and acute ischemic stroke. Despite the positive financial metrics, Hyperfine noted a net loss of $44.24 million for the year. The company plans to continue its momentum into 2024 with revenue expectations of up to $15 million and an ongoing focus on research and innovation.
Read more →HYPRHyperfine, Inc. Reports Third Quarter 2023 Financial Results
Hyperfine, Inc. reported its financial results for the third quarter of 2023, showing revenues of $2.33 million and a gross margin of 48%. The company achieved FDA clearance for its new AI-powered software and is advancing multiple clinical programs, including a feasibility study for Alzheimer's. Despite a net loss of $10.76 million, there was a notable decrease from the previous year's loss. Hyperfine's guiding revenue for the full year is projected between $11 to $13 million.
Read more →HYPR▲ +7.3%on this news
Hyperfine, Inc. Reports Second Quarter 2023 Financial Results
Hyperfine, Inc. reported its second quarter financial results for 2023, announcing record revenue of over $3.3 million, a significant increase from $1.53 million in Q2 2022. The company sold 14 Swoop systems during this period, marking a strong interest in its portable MRI technology. Despite these positive developments, Hyperfine faced a net loss of $10.64 million, although this reflects an improvement from the previous year's loss. Looking ahead, management anticipates full-year revenues between $10 to $14 million and a cash burn of $40 to $45 million.
Read more →HYPR▲ +35.5%on this news
Hyperfine, Inc. Announces Promotion of Tom Teisseyre, Ph.D. to Chief Operating Officer GUILFORD, Connecticut –
Hyperfine, Inc. has promoted Tom Teisseyre, Ph.D. to Chief Operating Officer, reflecting his contributions and leadership in medical imaging technology. Dr. Teisseyre, who previously served as Chief Product Officer, has a strong background in medical devices, particularly in surgical and implantable devices. Concurrently, Khan Siddiqui, M.D., will transition to a part-time role as Chief Medical Officer and Chief Strategy Officer for personal reasons but will remain an active strategic contributor. This transition occurs as Hyperfine continues to enhance its Swoop system, the world's first portable MRI device, focused on improving patient care and diagnostic imaging accessibility.
Read more →HYPRHyperfine, Inc. Reports First Quarter 2023 Financial Results
Hyperfine, Inc. reported its first quarter 2023 financial results, showcasing a record revenue of $2.6 million, up from $1.51 million year-over-year. The company successfully installed 10 new Swoop systems, improving its gross margin significantly. Despite a net loss of $12.16 million, there was a notable reduction from the prior year’s loss. Management anticipates total revenue for 2023 to be between $10 and $14 million as they continue financial discipline and aim to extend their cash runway through 2025.
Read more →HYPRHyperfine, Inc. to Announce First Quarter Financial Results on May 11, 2023
Hyperfine, Inc. (Nasdaq: HYPR) announced it will report its first quarter financial results on May 11, 2023. The company is known for creating the Swoop® system, which is the first FDA-cleared portable MRI system, enhancing accessibility to brain imaging at the point of care. A conference call will accompany the announcement, allowing investors to engage directly with management. Hyperfine aims to improve patient care through innovative and accessible imaging solutions.
Read more →HYPR▲ +10.7%on this news
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
Hyperfine, Inc. has reported financial results for both the fourth quarter and full year of 2022, announcing a significant increase in revenue to $6.814 million from $1.496 million in 2021. The company achieved multiple FDA clearances for its Swoop portable MRI system and continued expansion in commercial placements. Despite the positive revenue growth, Hyperfine also reported a net loss of $73.164 million for the year, prompting concerns about financial sustainability as it anticipates substantial cash burn in 2023. The outlook remains optimistic with projected revenues for 2023 between $10 million and $14 million.
Read more →HYPR▲ +23.7%on this news
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 21, 2023
Hyperfine, Inc. announced it will release its financial results for Q4 and the full year 2022 on March 21, 2023. The company, known for its Swoop® portable MRI system, is poised to discuss growth and financial health during a conference call. The Swoop® system has gained recognition for its innovative approach to neuroimaging at the point of care, enhancing diagnostic capabilities. Management encourages investors to access the live audio webcast and participate in the upcoming call.
Read more →HYPR▲ +15.8%on this news
Hyperfine, Inc. Receives FDA Clearance for Updated Software to Further Improve Diffusion-Weighted Imaging
Hyperfine, Inc. has received FDA 510(k) clearance for an updated version of its Swoop® system software, which significantly enhances diffusion-weighted imaging. The new software boasts a 42% improvement in signal-to-noise ratio and better compensation for patient motion, leading to higher image quality. This improvement is essential for accurately diagnosing neurological conditions and monitoring stroke patients, making the Swoop® system an invaluable tool for clinicians in neurocritical care. The updated software is scheduled for rollout to customers in March 2023.
Read more →HYPRHyperfine, Inc. Swoop Portable MR Imaging System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations CE Marking for the company's portable MRI system with AI-powered imaging software demonstrates that
Hyperfine, Inc. has announced that its Swoop Portable MR Imaging System has received CE Marking, signifying compliance with the EU's Medical Device Regulations. This achievement allows for potential future expansion into the European Economic Area while the company maintains its commercial focus in the U.S. The CE Marking highlights the system's adherence to rigorous safety and performance standards, marking a significant milestone for Hyperfine.
Read more →HYPRHyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop Portable MR Imaging System
Hyperfine, Inc. has received FDA 510(k) clearance for its upgraded AI-powered software for the Swoop Portable MR Imaging System, enhancing the quality of brain imaging. The new software improves the diffusion-weighting imaging sequence and increases the system's field of view by 10%. This development is part of Hyperfine's ongoing efforts to optimize the Swoop system's clinical utility and drive commercial adoption across healthcare institutions worldwide. The Swoop system, which first received FDA clearance in 2020, continues to demonstrate significant advancements in neuroimaging technology.
Read more →HYPR▲ +8.9%on this newsshared move
Hyperfine, Inc. Announces Brett Hale as New Chief Administrative Officer & Chief Financial Officer GUILFORD, CONNECTICUT
Hyperfine, Inc. has announced the appointment of Brett Hale as its new Chief Administrative Officer and Chief Financial Officer, effective February 13, 2023. Hale, who possesses over 25 years of experience in financial roles within the medical technology sector, will replace Alok Gupta, who is stepping down after a transition period. CEO Maria Sainz expressed excitement about Hale's potential to enhance the company's operations and drive the global adoption of their innovative Swoop portable MRI system. This transition comes as Hyperfine continues to focus on expanding access to MRI technology.
Read more →HYPR▼ -5.1%on this newsshared move
Hyperfine Swoop Point-of-Care MRI System™ Takes the Stage at ISMRM with Twelve Abstract Inclusions
Hyperfine has announced that twelve abstracts related to its Swoop® Point-of-Care MRI System™ have been accepted for presentation at the upcoming ISMRM and ISMRT annual meeting in Toronto. The research highlights advancements in magnetic resonance imaging from leading institutions, focusing on innovative approaches such as diffusion-tensor imaging and super-resolution imaging. The Swoop® system is designed to enhance patient care by facilitating brain imaging at the bedside, aligning with Hyperfine's mission to improve accessibility in diagnostic imaging. The event will showcase cutting-edge research that supports the continued development of this portable MRI technology.
Read more →HYPR▼ -8%on this news
Hyperfine to Present at the 5th Annual Evercore ISI HealthCONx Conference
GUILFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world's first FDA-cleared portable MRI system™, today announced that the company will be participating in the upcoming 5th Annual Everco
Read more →HYPRHyperfine Reports Third Quarter 2022 Financial Results
Hyperfine Reports Third Quarter 2022 Financial Results GUILFORD, Connecticut, November 10, 2022 (GLOBE NEWSWIRE) Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop , the world's first FDA-cleared portable MRI system , today reported financial results for the quarter ended Sept
Read more →HYPRHyperfine to Announce Third Quarter 2022 Financial Results on November 10, 2022
GUILFORD, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the third quarter 2022 on Thursday, November 10, 2022. Company m
Read more →HYPR▲ +6.6%on this news
Hyperfine Names Maria Sainz President and Chief Executive Officer
Hyperfine Names Maria Sainz President and Chief Executive Officer GUILFORD, Connecticut, October 6, 2022 (GLOBE NEWSWIRE) Hyperfine, Inc. (Nasdaq: HYPR), ( Hyperfine or the Company ), the groundbreaking medical device company that created Swoop , the world's first FDA-cleared po
Read more →HYPRHyperfine to Participate in Upcoming Investor Conferences
GUILFORD, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that management will present at two upcoming conferences: Scott Huennekens, Interim President and Chief Executi
Read more →HYPR▲ +5.2%on this news· ran to -19% by day 1
Hyperfine Reports Second Quarter 2022 Financial Results
Hyperfine Reports Second Quarter 2022 Financial Results GUILFORD, Connecticut, August 10, 2022 (GLOBE NEWSWIRE) Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop , the world's first FDA-cleared portable MRI system , today reported financial results for the quarter ended June
Read more →HYPR▲ +11.8%on this news
Hyperfine to Announce Second Quarter 2022 Financial Results on August 10, 2022
GUILFORD, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the second quarter 2022 on Wednesday, August 10, 2022. Company m
Read more →HYPR▼ -5.1%on this news
Hyperfine Announces Zero Radiation Dose Rapid MR Imaging Test for Pediatric Hydrocephalus Patients
AUSTIN, Texas, July 14, 2022 (GLOBE NEWSWIRE) -- Today, at HA Connect!, the 17th annual national conference on hydrocephalus, Hyperfine—creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) device—announced a new software enhancement that enables brai
Read more →HYPR▲ +24.4%on this news
Hyperfine Announces CEO Transition
Launches global search for long-term CEO with Scott Huennekens to serve as interim President & CEO Reaffirms 2022 Financial Guidance GUILFORD, Conn., June 29, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), (“Hyperfine” or “the Company”), the groundbreaking medical dev
Read more →HYPR▲ +24.4%on this news
Hyperfine Announces CEO Transition Launches global search for long-term CEO with Scott Huennekens to serve as interim President & CEO Reaffirms 2022 Financial Guidance
Hyperfine Announces CEO Transition Launches global search for long-term CEO with Scott Huennekens to serve as interim President & CEO Reaffirms 2022 Financial Guidance GUILFORD, Connecticut, June 29, 2022 (GLOBE NEWSWIRE) Hyperfine, Inc. (Nasdaq: HYPR), ( Hyperfine or the Comp
Read more →HYPRHyperfine Announces Expansion into Australia and New Zealand with Medical Device Registration and Notification
GUILFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), creator of the Swoop® Portable MR Imaging System™, the world’s first US FDA-cleared portable magnetic resonance imaging (MRI) device, announced today that it has completed registration and notifica
Read more →HYPRHyperfine to Present at the 2022 Jefferies Global Healthcare Conference
GUILFORD, Conn., May 25, 2022 (GLOBE NEWSWIRE) -- Hyperfine (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that management will be presenting at the upcoming 2022 Jefferies Global Healthcare Conference in New York, New Y
Read more →HYPR▼ -17.9%on this news
Hyperfine Reports First Quarter 2022 Financial Results
Hyperfine Reports First Quarter 2022 Financial Results GUILFORD, Connecticut, May 11, 2022 (GLOBE NEWSWIRE) Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop , the world's first FDA-cleared portable MRI system , today reported financial results for the quarter ended March 31,
Read more →HYPRHyperfine to Announce First Quarter 2022 Financial Results on May 11, 2022
GUILFORD, Conn., April 20, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the first quarter 2022 on Wednesday, May 11, 2022. Company mana
Read more →HYPRHyperfine Reports Fourth Quarter and Full Year 2021 Financial Results
Hyperfine Reports Fourth Quarter and Full Year 2021 Financial Results GUILFORD, Connecticut, March 23, 2022 (GLOBE NEWSWIRE) Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop , the world's first FDA-cleared portable MRI system , today announc
Read more →HYPRDefining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 2022 2022 Hyperfine, Inc. Forward Looking Statements 2022 Hyperfine, Inc. | Confidential and Proprietary This presentatio
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 2022 2022 Hyperfine, Inc. Forward Looking Statements 2022 Hyperfine, Inc. | Confidential and Proprietary This presentation includes forward-looking statements within the meaning of
Read more →HYPRHyperfine to Announce Fourth Quarter and Full Year 2021 Financial Results
GUILFORD, CT, March 03, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the fourth quarter and full year 2021 on Wednesday, March 23, 2022
Read more →HYPRHyperfine to Present at the 42nd Annual Cowen Healthcare Conference
GUILFORD, Conn., March 01, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, today announced that the company will be participating in the upcoming 42nd Annual Cowen Healthcare
Read more →HYPR▲ +6.8%on this news
Hyperfine Appoints Chip Truwit, M.D. as Senior Medical Director
GUILFORD, Conn., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Hyperfine Inc. (Nasdaq:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, today announced the appointment of Dr. Chip Truwit as senior medical director. For more than 30 years, Truw
Read more →HYPRHyperfine Reports Preliminary Unaudited 2021 Revenue and Swoop System Installations
Hyperfine Reports Preliminary Unaudited 2021 Revenue and Swoop System Installations GUILFORD, Connecticut, January 10, 2022 (GLOBE NEWSWIRE) - Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop , the world's first FDA-cleared portable MRI s
Read more →HYPR▼ -13.2%on this news
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the " Form 8-K ") filed with the
CONDENSED COMBINED FINANCIAL INFORMATION terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the "Form 8-K") filed with the Securities and Exchange Commission (the "SEC") on December 28, 2021. Unless the context
Read more →HYPRHyperfine, Inc., creator of the first FDA-cleared portable MRI device, and Liminal Sciences, Inc. to be listed on Nasdaq through a business combination with HealthCor Catalio Acquisition Corp. The transaction will combin
creator of the first FDA-cleared portable MRI device, and Liminal Sciences, Inc. to be listed on Nasdaq through a business combination with HealthCor Catalio Acquisition Corp. CT, July 8, 2021 - Hyperfine, Inc. ("Hyperfine"), creator of the first U.S. Food and Drug Administrat
Read more →HYPRHyperfine’s Swoop™ Portable MR Imaging System Wins Gold Medical Design Excellence Award
Guilford, CT, May 18, 2021 (GLOBE NEWSWIRE) -- Hyperfine’s category-defining Swoop™ Portable MR Imaging System has been recognized as best in class with a Gold Medical Design Excellence Award (MDEA) in the Radiology, Imaging, and Electromechanical Devices category. Medical Device
Read more →HYPRHyperfine Research Brings the Category-Defining Swoop™ Portable MR Imaging System on the Road with Demo at Your Door™
Guilford, CT, May 13, 2021 (GLOBE NEWSWIRE) -- Hyperfine Research is bringing its category-defining Swoop™ Portable MR Imaging System on the road so that healthcare professionals can participate in hands-on demonstrations. Swoop™ wheels directly to the patient’s bedside, plugs in
Read more →HYPRHyperfine’s Swoop™ Portable MR Imaging System Chosen from among 4,000 submissions as a Fast Company World Changing Idea
Guilford, CT, May 04, 2021 (GLOBE NEWSWIRE) -- Fast Company Magazine has recognized Hyperfine’s category-defining Swoop™ Portable MR Imaging System as a World Changing Idea with honorable mentions in two categories: World Changing Ideas of North America and World Changing Ideas i
Read more →HYPRHyperfine Dismantles the Traditional Experience for Acquiring Capital Medical Equipment with Launch of its Total Rethink Buying Process™.
Guilford, CT, March 30, 2021 (GLOBE NEWSWIRE) -- Hyperfine Research, the company redefining MR imaging with its Swoop™ Portable MR Imaging System, is pioneering a wholesale simplification of the capital equipment purchasing experience with the launch of its Total Rethink Buying P
Read more →HYPRHyperfine Raises $90 Million in Oversubscribed Series D Financing
Guilford, CT, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Hyperfine Research has closed an oversubscribed $90 Million Series D financing round, with support from investors including GV (formerly Google Ventures), Nextrans (KClavis-Nextrans), Axiom Associates, Huami, Colle Capital, LSS, and
Read more →HYPRINDEX TO FINANCIAL STATEMENT Audited Financial Statements for HealthCor Catalio Acquisition Corp.: Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPOR
INDEX TO FINANCIAL STATEMENT Audited Financial Statements for HealthCor Catalio Acquisition Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC To the Shareholders and
Read more →HYPRHyperfine’s Swoop™ Portable MR Imaging System Recognized as 2021 Innovation Awards Honoree by CES
Guilford, CT, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Hyperfine has been named a CES® 2021 Innovation Awards Honoree for its category-defining Swoop™ Portable MR Imaging system. The announcement was made ahead of the virtual CES 2021, one of the world’s most influential technology even
Read more →HYPRHyperfine Initiates Global Research Program Using Portable MR Imaging Technology To Identify and Mitigate Infant Brain Injury
Guilford, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Hyperfine is initiating a global research program supported by a $1.6 million grant from the Bill & Melinda Gates Foundation to investigate whether portable magnetic resonance imaging (MRI) in low-resource countries without readily-
Read more →HYPRHyperfine Wins incubatED Medical Device Innovation Challenge at 2020 American College of Emergency Physicians Meeting
Guilford, CT, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Hyperfine has won the American College of Emergency Physicians (ACEP) 2020 incubatED Medical Device Innovation Challenge, recognizing the company’s Swoop™ Portable MR Imaging System as an innovation that will shape the future of eme
Read more →HYPRHyperfine Receives Frost & Sullivan Best Practices Product Innovation Award For World’s First Truly Portable MR Imaging Technology
Guilford, CT, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Hyperfine has received a Best Practices Product Innovation award from Frost & Sullivan for the company’s category-defining portable MR imaging technology. Analysts from Frost & Sullivan, a leading growth strategy and research firm,
Read more →Competitive Position
How HYPR ranks across every disease it competes inCompetitive Position is a premium feature
See how HYPR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial